Diagnosis and Epidemiology of Cirrhosis

Lefton, Harvey B.; Rosa, A De; Cohen, Matthew

doi:10.1016/j.mcna.2009.03.002

Cited by 97 publications

(87 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cirrhotic patients with portal hypertension commonly develop ascites, which itself is associated with SBP, HRS and even death [1][2][3][4][5] . Ascitic fluid promulgation further involves the dysregulation of the renin-angiotensin-aldosterone axis and the resultant alterations in vascular tone and volume control [4,5] .…”

Section: Discussionmentioning

confidence: 99%

“…This process is driven by hepatic inflammatory processes in the setting of an inciting agent, such as hepatitis C virus (HCV), alcohol (ETOH) abuse or a metabolic derangement in a host with a particular genetic constitution [1][2][3][4] . Decompensated cirrhosis is identified by the presence of portal hypertensive clinical sequelae, namely hepatic encephalopathy, varices, and most commonly, ascites.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites

Attar

Moore

George

et al. 2014

WJG

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites

Attar

Moore

George

et al. 2014

WJG

View full text Add to dashboard Cite

show abstract

“…Chronic hepatitis B (CHB) is an urgent global public health problem that affects 350-400 million people worldwide (1). In China, 7% of individuals are diagnosed as carriers of hepatitis B virus (HBV) (2).…”

Section: Introductionmentioning

confidence: 99%

Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis

Gai

Wang

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Chronic hepatitis B virus (CHB) infection is a burden on global healthcare and is associated with a higher risk of serious sequelae, including cirrhosis and hepatocellular carcinoma. The clinical application of entecavir as a treatment for CHB has produced positive outcomes, and so is an attractive form of pharmacological therapy. However, little data exists comparing the safety and efficacy of entecavir for the treatment of hepatitis B virus (HBV)-related compensated, and decompensated cirrhosis, respectively. The aim of the present study was to evaluate entecavir therapy as a treatment for patients with HBV-related compensated and decompensated cirrhosis. A retrospective analysis of 46 compensated patients (compensated group) and 51 decompensated cirrhotic patients (decompensated group) treated with entecavir was conducted. Baseline demographics, clinical outcomes, and adverse events during the treatment were compared. Treatment with entecavir for 96 weeks resulted in significant improvements in serum levels of HBV DNA (P=0.002), albumin (P=0.014), cholinesterase (CHE; P=0.001), HBV DNA negativity rate (P=0.004), Child-Turcotte-Pugh score (P=0.030), alanine aminotransferase normalized rate (P=0.039), and the degree of esophageal varices liver stiffness (P=0.002) in the two groups. However, statistical analysis revealed that the improvements were significantly higher in the compensated group compared with the decompensated group (P<0.05). The complement component (C)3 and C4 levels were also significantly increased in the compensated group compared with the decompensated group at weeks 24, 48 and 96 (P<0.05). In addition, the incidences of hepatocellular carcinoma, upper digestive tract hemorrhage and ascites were significantly higher in the decompensated group compared with the compensated group (P<0.05). In conclusion, treatment with 96-week entecavir therapy produced similar clinical outcomes in compensated and decompensated cirrhotic patients via inhibiting HBV-DNA viral load and recovering complement C3 and C4; however, entecavir exerts a better effect on patients with compensated cirrhosis, and so this therapy may improve the prognosis of such patients.

show abstract

“…6,7 HCV prevention and control depends on a complex assessment of HCV infection, which involves correlation of risk factors and estimation of factors that accelerate disease progression. 8,9 Because there is no vaccine for HCV, or any type of post-exposure prophylaxis, proper epidemiological evaluation is essential for planning primary HCV prevention in any population. Follow-up of HCV-positive individuals by the healthcare team is of utmost importance, rather than sporadic medical evaluation.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C: evaluation of outcomes and georeferencing of cases in Santa Cruz do Sul, Brazil, between 2002 and 2015. A cross-sectional study

et al. 2017

View full text Add to dashboard Cite

Diagnosis and Epidemiology of Cirrhosis

Cited by 97 publications

References 43 publications

Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites

Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites

Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis

Hepatitis C: evaluation of outcomes and georeferencing of cases in Santa Cruz do Sul, Brazil, between 2002 and 2015. A cross-sectional study

Contact Info

Product

Resources

About